If you have advanced cancer that is no longer responding to treatment, you may be eligible for an investigational drug (seribantumab) through the CRESTONE study, but you must first have your doctor genetically test your tumor to see if you qualify.


CRESTONE is a clinical trial that is testing an investigational treatment for patients with any solid tumor that has tested positive for an NRG1 fusion.


Pinpoint Patient Recruiting is working with Elevation Oncology to raise awareness about the CRESTONE Study. Click here to learn more about Pinpoint Patient Recruiting. We take privacy and your personal information very seriously. Please click here to read our full privacy policy.



Want to know if you qualify?

Fill out the form below to find out if you qualify or to ask questions about the study.  Our team can answer questions about genomic testing, the trial criteria and connect you to a doctor's office where the study is taking place.